Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31053240 | 1.00 | PKM (0.44) | PKMPTGS2NLRP3CYP4F2CYP4A11 | |
| SCHEMBL34471549 | 0.85 | CYP4F2 (0.57) | NLRP3CYP4F2CYP4A11KMT2AALDH1A1 | |
| SCHEMBL5009319 | 0.84 | NLRP3 (0.50) | PKMPTGS2NLRP3CYP4F2CYP4A11 | |
| SCHEMBL31284578 | 0.84 | KDM4E (0.43) | CYP4F2CYP4A11L3MBTL1KMT2ATDP1 | |
| SCHEMBL2420372 | 0.84 | PKM (0.47) | PKMNLRP3CYP4F2CYP4A11L3MBTL1 | |
| SCHEMBL27984139 | 0.84 | KDM4E (0.43) | CYP4F2CYP4A11L3MBTL1KMT2ATDP1 | |
| SCHEMBL852520 | 0.83 | PKM (0.53) | PKMNLRP3CYP4F2CYP4A11L3MBTL1 | |
| SCHEMBL29511550 | 0.83 | PKM (0.53) | PKMNLRP3CYP4F2CYP4A11L3MBTL1 | |
| SCHEMBL23218990 | 0.83 | PKM (0.46) | PKMNLRP3CYP4F2CYP4A11KMT2A | |
| SCHEMBL30950183 | 0.83 | PKM (0.46) | PKMNLRP3CYP4F2CYP4A11KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025262295-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| EP-4667466-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | Dark Blue Therapeutics Ltd (GB) | 2025-12-24 | — | — | EP | disclosed |
| US-9849109-B2 | Autotaxin inhibitors and uses thereof | AMIRA PHARMACEUTICALS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9849109-B2 | Autotaxin inhibitors and uses thereof | AMIRA PHARMACEUTICALS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9849109-B2 | Autotaxin inhibitors and uses thereof | AMIRA PHARMACEUTICALS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| EP-2606031-B1 | AUTOTAXIN INHIBITORS AND USES THEREOF | AMIRA PHARMACEUTICALS INC (US) | 2017-09-27 | — | — | EP | disclosed |
| EP-2606031-B1 | AUTOTAXIN INHIBITORS AND USES THEREOF | AMIRA PHARMACEUTICALS INC (US) | 2017-09-27 | — | — | EP | disclosed |
| EP-2794563-B1 | HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2017-02-22 | — | — | EP | disclosed |
| US-20150164861-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | AMIRA PHARMACEUTICALS, INC. (US) | 2015-06-18 | — | — | US | disclosed |
| US-20150164861-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | AMIRA PHARMACEUTICALS, INC. (US) | 2015-06-18 | — | — | US | disclosed |
| US-20150164861-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | AMIRA PHARMACEUTICALS, INC. (US) | 2015-06-18 | — | — | US | disclosed |
| US-9000025-B2 | Autotaxin inhibitors and uses thereof | AMIRA PHARMACEUTICALS, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-9000025-B2 | Autotaxin inhibitors and uses thereof | AMIRA PHARMACEUTICALS, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-9000025-B2 | Autotaxin inhibitors and uses thereof | AMIRA PHARMACEUTICALS, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| EP-2606031-A2 | AUTOTAXIN INHIBITORS AND USES THEREOF | Amira Pharmaceuticals, Inc. (US) | 2013-06-26 | — | — | EP | disclosed |
| US-20130150326-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | AMIRA PHARMACEUTICALS, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130150326-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | AMIRA PHARMACEUTICALS, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130150326-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | AMIRA PHARMACEUTICALS, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| WO-2012024620-A2 | AUTOTAXIN INHIBITORS AND USES THEREOF | AMIRA PHARMACEUTICALS, INC. (US) | 2012-02-23 | — | — | WO | disclosed |
| WO-2012024620-A2 | AUTOTAXIN INHIBITORS AND USES THEREOF | AMIRA PHARMACEUTICALS, INC. (US) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150326-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | ENPP2, SERPINB1, SERPINE1 | PKM 4458/4885PTGS2 3675/4885NLRP3 512/4885 |
| US-20150164861-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | ENPP2, SERPINB1, SERPINE1 | PKM 4458/4885PTGS2 3675/4885NLRP3 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.